ID: ALA464300

Max Phase: Preclinical

Molecular Formula: C16H19Cl2FN2O2

Molecular Weight: 324.78

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cl.FC[C@@H]1CO[C@@](CCc2ccc(Cl)cc2)(Cn2ccnc2)O1

Standard InChI:  InChI=1S/C16H18ClFN2O2.ClH/c17-14-3-1-13(2-4-14)5-6-16(11-20-8-7-19-12-20)21-10-15(9-18)22-16;/h1-4,7-8,12,15H,5-6,9-11H2;1H/t15-,16-;/m1./s1

Standard InChI Key:  JMODIHVGSKZBOC-QNBGGDODSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 324.78

Molecular Weight (Monoisotopic): 324.1041

AlogP: 3.25

#Rotatable Bonds: 6

Polar Surface Area: 36.28

Molecular Species: NEUTRAL

HBA: 4

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.43

CX LogP: 3.47

CX LogD: 3.43

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.82

Np Likeness Score: -0.52

References

1. Vlahakis JZ, Kinobe RT, Nakatsu K, Szarek WA, Crandall IE..  (2006)  Anti-Plasmodium activity of imidazole-dioxolane compounds.,  16  (9): [PMID:16495054] [10.1016/j.bmcl.2006.01.122]

2. Vlahakis JZ, Hum M, Rahman MN, Jia Z, Nakatsu K, Szarek WA..  (2009)  Synthesis and evaluation of imidazole-dioxolane compounds as selective heme oxygenase inhibitors: effect of substituents at the 4-position of the dioxolane ring.,  17  (6): [PMID:19268600] [10.1016/j.bmc.2009.01.078]

Source

Source(1):

• Scientific Literature